www.MarketResearchReports.com

Parkinson's Disease

Therapeutics Market to 2019 - Pipeline Shows Shift Towards

Long Term Disease

ManagementCategory : Diseases / Healthcare

All logos and Images mentioned on this slide belong to their respective owners.

www.MarketResearchReports.com

Introduction to Report

Launch Date: December 15, 2013

Number of Pages: 130

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 3,500

Price For Site License: USD 7,000

Price For Global User License: USD 10,500

Delivery Time: Within 24 Hours (During Working Days)

www.MarketResearchReports.com

About the Report

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s Disease (PD) market is expected to decline from $3.4 billion in 2012 to $2.9 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 2.3%.

www.MarketResearchReports.com

Research Findings

The latest report states that Parkinson’s Disease (PD) drugs, such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone), will lose their patents by the end of the forecast period. Generic alternatives for these treatments have already been approved, which will result in further market competition.

Additionally, the loss of patent for Mirapex (pramipexole dihydrochloride) and Exelon (rivastigmine tartrate) in 2010 and 2012 will continue to halt future PD market growth.

www.MarketResearchReports.com

Reasons to Buy

Understand the different levels of PD therapy from early-stage to advanced

Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent

Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for PD therapeutics

Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for PD therapeutics

Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the PD therapeutics market

www.MarketResearchReports.com

Report Coverage

1. Introduction

2. Marketed Products

3. Pipeline for Parkinson’s Disease

4. Market Forecast to 2019

5. Deals and Strategic Consolidations

6. Appendix

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.

www.MarketResearchReports.com

Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

www.MarketResearchReports.com

How To Buy This Report?

Visit following URL to see Table of Content and purchase this publication:

http://www.marketresearchreports.com/gbi-research/parkinsons-disease-therapeutics-market-2019-pipeline-shows-shift-towards-long-term

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : info@marketresearchreports.comPhone: +1 302-703-7787 (USA) +91-8762746600 (India)